港股異動 | 德琪醫藥-B漲7% XPOVIO®上市申請獲新加坡HSA批准
格隆匯3月2日丨德琪醫藥-B(6996.HK)盤中漲7.4%,報6.68港元,總市值44億港元。德琪醫藥-B今日公佈,XPOVIO®(塞利尼索)已獲得新加坡衞生科學局(HSA)的上市許可,用於以下三個適應症的治療:1、塞利尼索聯合硼替佐米和地塞米松治療接受過至少1種既往治療的復發難治性多發性骨髓瘤患者;2、塞利尼索聯合地塞米松治療接受過至少4種既往治療且對至少兩種蛋白酶體抑制劑、兩種免疫調節劑及一種抗CD38單克隆抗體藥物存在難治的復發難治性多發性骨髓瘤成人患者;3、塞利尼索單藥用於治療接受過至少2種既往治療且無法接受造血幹細胞移植的復發難治性瀰漫性大B細胞淋巴瘤成人患者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.